Mar 08, 2022 / 06:30PM GMT
Tyler Martin Van Buren - Cowen and Company, LLC, Research Division - Analyst
Great. Good afternoon, everyone. Welcome, again, to Cowen's 42nd Annual Healthcare Conference. Thank you very much for joining us. My name is Tyler Van Buren. I'm a senior biotech analyst at Cowen. For our next session, we have a fireside chat with Regeneron. And it is my pleasure to introduce Bob Landry, the Chief Financial Officer and Executive Vice President of Finance and Neil Stahl, the Executive Vice President of R&D.
Bob and Neil, it's a pleasure to have you. Thank you very much for being here.
Robert E. Landry - Regeneron Pharmaceuticals, Inc. - Executive VP of Finance & CFO
Tyler, thanks for the invite. Always happy to be invited to the Cowen conference. Let me begin with our forward-looking statement. I'll get into some kind of opening remarks, and then we'll jump right into questions for Neil and myself.
So again, to remind the audience remarks made today include forward-looking statements about Regeneron. Each forward-looking statement is subject
Regeneron Pharmaceuticals Inc at Cowen Health Care Conference (Virtual) Transcript
Mar 09, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers